A Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Octreotide LAR for Patients with Advanced Neuroendocrine Cancers

• Published in: Cancer investigation Vol. 34; no. 5; pp. 213 - 219
• Main Authors: Bendell, Johanna C., Zakari, Ahmed, Lang, Evan, Waterhouse, David, Flora, Douglas, Alguire, Kathryn, McCleod, Michael, Peacock, Nancy, Ruehlman, Peter, Lane, Cassie M., Earwood, Chris, Shih, Kent
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 27.05.2016
• Subjects: Adult; Aged; Aged, 80 and over; Angiogenesis; Antibodies, Monoclonal, Humanized - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Bevacizumab - administration & dosage; Combined Modality Therapy; Female; Humans; Male; Middle Aged; Monoclonal antibodies; Neoplasm Staging; Neuroendocrine Tumors - drug therapy; Neuroendocrine Tumors - mortality; Neuroendocrine Tumors - pathology; Octreotide - administration & dosage; Pancreatic cancer; Retreatment; Treatment Outcome; Monoclonal antibodies; Angiogenesis; Pancreatic cancer
• ISSN: 0735-7907; 1532-4192
• DOI: 10.3109/07357907.2016.1174257

Purpose: To evaluate efficacy and safety of bevacizumab, pertuzumab, and octreotide depot for advanced neuroendocrine tumors. Methods: Patients received bevacizumab 15 mg/kg and pertuzumab 420 mg IV q21 days with octreotide depot 30 mg IM q28 days. Results: Toxicities in 43 patients included diarrhea (63%), fatigue (63%), hypertension (44%), and nausea (44%). Reversible G3 hypertension (26%) and LVEF decline (9%) occurred. 7/43 patients achieved objective response (typical carcinoid, 5; pancreatic NET, 2). Median PFS and OS were 6.5 and 26.4 months, respectively. Discussion: Bevacizumab, pertuzumab, and octreotide depot was well-tolerated with a 16% ORR. Results in the well-differentiated carcinoid tumors are thought provoking.